Arbutus Biopharma Newsroom

Arbutus to Present Imdusiran Data at EASL Congress 2024

WARMINSTER, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to

GlobeNewswireMay 22 02:00 ET

Genevant Sciences And Arbutus Biopharma Win Dismissal Of An Action By Acuitas Therapeutics (Partnered With Pfizer On Vaccine Delivery Systems) Seeking A Declaratory Judgement That The Pfizer Comirnaty Vaccine Does Not Infringe Arbutus Patents

Genevant Sciences And Arbutus Biopharma Win Dismissal Of An Action By Acuitas Therapeutics (Partnered With Pfizer On Vaccine Delivery Systems) Seeking A Declaratory Judgement That The Pfizer Comirnaty

BenzingaMay 20 12:52 ET

Sector Update: Health Care Stocks Softer Friday Afternoon

Health care stocks eased Friday afternoon with the NYSE Health Care Index down 0.1% and the Health Care Select Sector SPDR Fund (XLV) marginally higher. The iShares Biotechnology ETF (IBB) fell 0.3%.

MT NewswiresMay 17 13:53 ET

Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program

Arbutus Biopharma (ABUS) shareholder Whitefort Capital Management issued an open letter to shareholders Friday urging the company to stop further share issuances and explore strategic alternatives for

MT NewswiresMay 17 10:40 ET

Express News | Shares of Arbutus Biopharma up 2.4% Premarket After Investor Whitefort Urges Co to Halt Stock Sales, Find Partner

ReutersMay 17 09:18 ET

Express News | Whitefort Capital: Calls on Arbutus to Cease Any Further Share Issuances & Plans to Vote Against Proposed Share Increases to Co's Incentive Plan

ReutersMay 17 09:02 ET

Express News | Whitefort Capital: Owns About 6.8% of Arbutus Biopharma's Outstanding Shares

ReutersMay 17 09:01 ET

Express News | Whitefort Capital: Urges Arbutus Biopharma to Launch a Strategic Review of Its Hepatitis B Virus Portfolio by Yearend

ReutersMay 17 09:01 ET

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

Asserts Arbutus' Share of Patent Infringement Claims Against Moderna and Pfizer/BioNTech is Potentially Worth Billions of Dollars and Preserving that Value Should be a Key Focus Calls on Arbutus to Cease Any Further

BusinesswireMay 17 09:00 ET

Express News | Whitefort Capital Management- Hope to Continue to Work Constructively, Collaboratively With Arbutus Biopharma's Board on These Critical Initiatives

ReutersMay 9 08:11 ET

Express News | Whitefort Capital Management- Requested That Arbutus Biopharma's Board Explore All Strategic Options for Hepatitis B Virus (Hbv) Portfolio

ReutersMay 9 08:10 ET

Express News | Whitefort Capital Management- Requested That Arbutus Biopharma's Board Immediately Terminate Atm Program

ReutersMay 9 08:09 ET

Express News | Whitefort Capital Management-Conveyed Their View to Arbutus Biopharma's Board That Current Market Price of Shares Does Not Reflect Intrinsic Value

ReutersMay 9 08:08 ET

Express News | Whitefort Capital Management, LP - Purchased Arbutus Biopharma's Securities Based on Belief That Such Securities, When Purchased, Were Undervalued

ReutersMay 9 08:07 ET

Express News | Whitefort Capital Management, LP Reports 6.8% Stake in Arbutus Biopharma Corp as of May 2, 2024 - SEC Filing

ReutersMay 9 08:06 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Hologic (HOLX) and Arbutus Biopharma (ABUS)

TipRanksMay 8 00:41 ET

Arbutus to Participate in Two Upcoming Investor Conferences

WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a fu

Arbutus BiopharmaMay 7 00:00 ET

The Arbutus Biopharma Corporation (NASDAQ:ABUS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Last week saw the newest quarterly earnings release from Arbutus Biopharma Corporation (NASDAQ:ABUS), an important milestone in the company's journey to build a stronger business. Revenues fell

Simply Wall StMay 5 08:37 ET

Global RNAi Therapeutics Market Insights & Forecasts With Potential Impact of COVID-19 2024-2028 Featuring Sanofi, Alnylam, Arrowhead, Arbutus Biopharma, Benitec Biopharma, Sirnaomics - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global RNAi Therapeutics Market (By Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been add

BusinesswireMay 3 09:35 ET

Express News | Chardan Capital Reiterates Buy on Arbutus Biopharma, Maintains $4 Price Target

BenzingaMay 3 09:21 ET